Compare ResMed Inc. (RMD) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs S&P500 ETF — how do they compare? ResMed Inc. trades at $229.72 (market cap $31.89B), while S&P500 ETF trades at $778.34 (market cap $821.54B). The key difference: S&P500 ETF is far larger — about 25.8× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.16% dividend while S&P500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and S&P500 ETF for 205 Days on average.
| RMD | SPY | |
|---|---|---|
Market Cap | $31.89B | $821.54B |
Volume | 618,314 | 40,070,358 |
Sector | Health | — |
52-Week High | $277.88 | $779.14 |
52-Week Low | $182.82 | $631.99 |
Typical Hold Time | 51 Days | 205 Days |
Enterprise Value | $31.24B | — |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
SPY, tracking the S&P 500, trades at $775.78, down 0.19% on the day amid a mixed technical backdrop with a bullish moving average signal but neutral oscillators. The ETF shows no available fundamental ratios in this snapshot, and a dividend of $1.89 is scheduled for payment in October 2026. Recent news highlights market volatility, with articles discussing valuation concerns and sector rotations.
The outlook for SPY hinges on broader market trends, with technical support near $771 offering a cushion. Risks include potential earnings growth slowdowns and macroeconomic pressures, but the bullish moving average alignment suggests underlying strength for long-term investors focused on U.S. equity exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
